The mechanisms of cardiovascular protective effects of ghrelin and its synthetic analogs are still largely unknown. Our first aim was to ascertain whether or not natural and synthetic ligands of GHS-R1a are capable of interfering with the activity of the renin-angiotensin system. Second, since polymorphisms in the ACE gene have been associated with Alzheimer's dementia (AD) and ACE is potentially involved in brain β-amyloid degradation, we also investigated the state of ghrelin axis and inflammatory markers in patients with AD and vascular dementia (VaD). Desacyl ghrelin, hexarelin, EP80317, and GHRP-6 all significantly inhibited ACE activity in vitro; by comparison, the efficacies of ghrelin and MK-0677 were significantly lower, suggesting that ACE-inhibiting activity is unrelated to ligand affinity to GHS-R1a. ACE was capable of cleaving Aβin vitro, reducing its ability to aggregate in fibrillar Aβ. Interestingly, this protective effect of ACE was blunted by enalapril but not hexarelin or EP80317. Desacyl ghrelin levels were lower in VaD subjects compared with AD and control subjects, whereas ghrelin and TNF-α levels were similar in all groups. VaD subjects demonstrated greater levels of mRNA for GHS-R1a, PPAR-γ and CD36 in peripheral blood lymphocytes compared with other groups. In conclusion, some GHSs are effective ACE-inhibitors, and this activity may contribute to their cardiovascular effects. Hexarelin or EP80317 do not inhibit the N-domain of ACE, which is also involved in the metabolism of β-amyloid, suggesting the possibility of developing new antihypertensive drugs with improved therapeutic potential.

Torsello, A., Bresciani, E., Ravelli, M., Rizzi, L., Bulgarelli, I., Ricci, G., et al. (2012). Novel domain-selective ACE-inhibiting activity of synthetic growth hormone secretagogues. PHARMACOLOGICAL RESEARCH, 66(4), 317-324 [10.1016/j.phrs.2012.06.006].

Novel domain-selective ACE-inhibiting activity of synthetic growth hormone secretagogues

TORSELLO, ANTONIO BIAGIO
;
BRESCIANI, ELENA;RIZZI, LAURA;BULGARELLI, ILARIA;DEL PUPPO, MARINA;MAININI, VERONICA;TAMIAZZO, LAURA;MANCIA, GIUSEPPE;MAGNI, FULVIO;LOCATELLI, VITTORIO
2012

Abstract

The mechanisms of cardiovascular protective effects of ghrelin and its synthetic analogs are still largely unknown. Our first aim was to ascertain whether or not natural and synthetic ligands of GHS-R1a are capable of interfering with the activity of the renin-angiotensin system. Second, since polymorphisms in the ACE gene have been associated with Alzheimer's dementia (AD) and ACE is potentially involved in brain β-amyloid degradation, we also investigated the state of ghrelin axis and inflammatory markers in patients with AD and vascular dementia (VaD). Desacyl ghrelin, hexarelin, EP80317, and GHRP-6 all significantly inhibited ACE activity in vitro; by comparison, the efficacies of ghrelin and MK-0677 were significantly lower, suggesting that ACE-inhibiting activity is unrelated to ligand affinity to GHS-R1a. ACE was capable of cleaving Aβin vitro, reducing its ability to aggregate in fibrillar Aβ. Interestingly, this protective effect of ACE was blunted by enalapril but not hexarelin or EP80317. Desacyl ghrelin levels were lower in VaD subjects compared with AD and control subjects, whereas ghrelin and TNF-α levels were similar in all groups. VaD subjects demonstrated greater levels of mRNA for GHS-R1a, PPAR-γ and CD36 in peripheral blood lymphocytes compared with other groups. In conclusion, some GHSs are effective ACE-inhibitors, and this activity may contribute to their cardiovascular effects. Hexarelin or EP80317 do not inhibit the N-domain of ACE, which is also involved in the metabolism of β-amyloid, suggesting the possibility of developing new antihypertensive drugs with improved therapeutic potential.
Articolo in rivista - Articolo scientifico
Hexarelin; ghrelin
English
317
324
8
Torsello, A., Bresciani, E., Ravelli, M., Rizzi, L., Bulgarelli, I., Ricci, G., et al. (2012). Novel domain-selective ACE-inhibiting activity of synthetic growth hormone secretagogues. PHARMACOLOGICAL RESEARCH, 66(4), 317-324 [10.1016/j.phrs.2012.06.006].
Torsello, A; Bresciani, E; Ravelli, M; Rizzi, L; Bulgarelli, I; Ricci, G; Ghiazza, B; DEL PUPPO, M; Mainini, V; Omeljaniuk, R; Tamiazzo, L; Mancia, G; Magni, F; Locatelli, V
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/36233
Citazioni
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 9
Social impact